Clinical Supply Chain Management: Why It Derails Studies

Clinical supply chain management is the least glamorous discipline in clinical operations — until it stops your trial dead. When investigational medicinal product (IMP) doesn't arrive at site on time, or stability data doesn't support the required storage conditions, or lab kits expire before they're used, everything else grinds to a halt. Patients can't be dosed. Data can't be collected. Milestones slip.

Yet supply chain planning is routinely treated as a logistical afterthought rather than a strategic workstream. Sponsors sign the CRO contract, design the protocol, and then discover — usually during start-up — that nobody has thought through how drug product gets manufactured, labelled, shipped, stored, tracked, and accounted for across a multi-site trial.

Here's where it goes wrong, and how to get it right.

The Supply Chain Is a Critical Path, Not a Support Function

Most trial timelines show patient enrolment as the critical path. That's only true if the drug is on the shelf when patients arrive. In practice, the IMP supply chain runs in parallel with site activation, and any slip in either one delays first patient in.

The supply chain for a clinical trial includes:

• IMP manufacturing and release — GMP manufacture, QC testing, batch release by a Qualified Person
• Primary and secondary packaging — including child-resistant packaging where required and protocol-specific labelling
• Blinding and randomisation packaging — for double-blind trials, this is a complex manufacturing step in its own right
• Depot management and distribution — storage under GDP-compliant conditions, temperature-controlled shipping, chain of custody
• Site-level inventory management — ensuring each site has enough stock without excessive wastage
• Returns, reconciliation, and destruction — accounting for every unit dispensed and returned

Each of these steps has its own lead times, quality requirements, and regulatory dependencies. Miss any one, and the whole chain stalls.

Where Supply Chains Fail: Five Common Failure Modes

1. Underestimating Manufacturing Lead Times

Clinical drug product manufacturing takes longer than sponsors expect, especially for early-phase programmes where the formulation is still being refined or the batch size is small and commercially unattractive for CMOs. A realistic timeline from manufacturing order to QP release is 12–16 weeks for a straightforward oral solid dose. Complex formulations, sterile products, or biologics can take 6–9 months.

The problem compounds when manufacturing is sequential with packaging and labelling. Plan these in parallel where possible — finalise label text while the batch is in QC, not after release.

2. Labelling Complexity and Regulatory Fragmentation

Clinical trial labelling is governed by country-specific requirements that often conflict. The EU Clinical Trials Regulation requires specific particulars in the national language(s) of each member state where the trial is conducted. The UK has its own post-Brexit requirements. Get the label wrong, and you're looking at a reprint — typically 3–4 weeks lost.

For multi-country trials, the solution is usually a booklet label system that accommodates multiple languages in a single fold-out label. But this needs to be designed early, reviewed by regulatory teams in each country, and factored into packaging lead times.

3. Poor Demand Forecasting

Demand forecasting for clinical trials is fundamentally different from commercial supply chain forecasting. You're not predicting consumer demand — you're predicting enrolment rates, screen failure rates, dose escalation patterns, and protocol amendment impacts, all of which are uncertain.

Common forecasting mistakes:

• Using optimistic enrolment projections without scenario planning for slow recruitment
• Not accounting for screen failures (which consume lab kits but not drug product)
• Failing to model the impact of protocol amendments on dosing requirements
• Ordering a single batch and having no contingency for manufacturing failures

The right approach is to build three scenarios — expected, best case, and worst case — and ensure your supply plan covers the worst case without excessive waste in the expected case.

4. Temperature Excursions and Cold Chain Failures

Cold chain management is a high-stakes game. Many IMPs require refrigerated (2–8°C) or frozen (-20°C or below) storage. A single temperature excursion during transit can render an entire shipment unusable — and trigger a costly investigation.

5. Inadequate Depot and Distribution Strategy

For UK-based trials, the depot strategy seems straightforward — a single UK depot shipping to UK sites. But even this simple model has pitfalls: courier lead times to remote sites, NHS trust receiving procedures that only accept deliveries on certain days, and site pharmacy opening hours that don't align with standard delivery windows.

For multi-country trials, the complexity multiplies. You need to decide between a centralised depot model (one or two EU depots shipping cross-border) and a local depot model (one depot per country). Centralised is cheaper but adds regulatory complexity around import licences and customs. Local is operationally simpler but more expensive and harder to rebalance stock between countries.

Interactive Response Technology: The Operational Backbone

Modern clinical supply management relies on Interactive Response Technology (IRT) — the system that manages randomisation, drug assignment, and inventory across sites. A well-configured IRT system is the difference between smooth operations and constant firefighting.

What good IRT configuration looks like:

• Automated resupply triggers — when site inventory falls below a threshold, the system generates a shipment request without manual intervention
• Real-time visibility — sponsors and supply managers can see stock levels at every site, in transit, and at depot
• Randomisation integration — treatment assignment is blinded, documented, and traceable
• Dose escalation support — for adaptive designs, the IRT must handle cohort-level unblinding and dose assignments dynamically
• Expiration management — automatic alerts when stock approaches its expiry date, preventing dispensing of expired product

Configuring the IRT is not a task for the week before site initiation. It needs to be specified during protocol finalisation, built and validated during start-up, and tested with end-to-end supply chain simulations before any patient is randomised.

Reconciliation and Accountability: The Regulatory Requirement

Every unit of IMP must be accounted for from manufacture to destruction. This isn't just good practice — it's a regulatory requirement under GMP Annex 13 (now Annex 6 under the EU GMP framework) and ICH E6(R2) section 8.

Reconciliation failures — where the numbers don't add up between what was shipped, what was dispensed, what was returned, and what was destroyed — are a common inspection finding. They suggest either poor documentation or, worse, diversion of product.

Building accountability into your process means:

• Standardised accountability logs at every stage — depot, transit, site pharmacy, patient
• Regular reconciliation reviews (at least monthly for active sites)
• Clear escalation procedures when discrepancies are identified
• Training for site pharmacy staff on documentation requirements specific to clinical trial IMP

Budgeting for Supply: The Hidden Costs

Clinical supply costs are frequently underestimated in trial budgets. Beyond the obvious cost of drug substance and manufacture, sponsors need to budget for:

• Packaging and labelling — often 15–25% of total supply costs for complex multi-language label requirements
• Depot fees — storage, handling, pick-pack-ship, and quality management
• Temperature-controlled shipping — qualified containers, data loggers, express courier services
• Overage — you need to manufacture 20–30% more drug product than your protocol requires to account for wastage, returns, and contingencies
• IRT licensing and configuration — often a separate line item that gets forgotten
• Returns and destruction — the cost of getting unused product back from sites and destroying it under witnessed conditions

A good rule: if your supply budget is less than 15% of your total trial budget, you've probably missed something.

The DEOX Approach

We treat clinical supply chain management as a strategic workstream from protocol design onwards. That means supply planning runs in parallel with regulatory strategy and site feasibility — not after them. We build demand forecasts with scenario planning, configure IRT systems that actually automate resupply, and maintain the documentation trail that keeps inspectors satisfied.

If you're planning a trial and want supply chain built in from the start — or you're running a trial where supply is already causing problems — let's talk.